Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | PSMB5 | P28074 | 5/20 | 0.47 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1027115 | 0.84 | KDM4E (0.62) | MAOBPSMB5PSMB8KDM4EMAPT | |
| Ammonia Solution, Strong SCHEMBL6385399 | 0.83 | KDM4E (0.60) | MAOBPSMB5PSMB8KDM4EMAPT | |
| SCHEMBL2985206 | 0.80 | MAOB (0.47) | MAOBPSMB5PSMB8KDM4EMAPT | |
| SCHEMBL18331257 | 0.79 | MAOB (0.54) | MAOBPSMB5PSMB8KDM4EMAPT | |
| SCHEMBL3147413 | 0.79 | MAOB (0.54) | MAOBPSMB5PSMB8KDM4EMAPT | |
| SCHEMBL21807603 | 0.77 | MAOB (0.51) | MAOBPSMB5PSMB8KDM4EMAPT | |
| SCHEMBL6511944 | 0.76 | MAOB (0.63) | MAOBPSMB5PSMB8KDM4ECA2 | |
| SCHEMBL21807589 | 0.75 | MAOB (0.50) | MAOBPSMB5PSMB8KDM4EMAPT | |
| SCHEMBL29171785 | 0.75 | MAOB (0.50) | MAOBPSMB5PSMB8KDM4EMAPT | |
| SCHEMBL734054 | 0.75 | KDM4E (0.55) | MAOBPSMB5PSMB8KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11377450-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| CN-112955142-A | Functionalized heterocyclic compounds as antiviral agents | 英安塔制药有限公司 | 2021-06-11 | — | — | CN | disclosed |
| US-20210115060-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2021-04-22 | — | — | US | disclosed |
| US-10865211-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| US-20200095258-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11377450-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | MAOB 805/4885PSMB5 293/4885PSMB8 1331/4885 |
| US-10865211-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | MAOB 805/4885PSMB5 293/4885PSMB8 1331/4885 |
| US-20210115060-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | MAOB 805/4885PSMB5 293/4885PSMB8 1331/4885 |
| US-20200095258-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | MAOB 805/4885PSMB5 293/4885PSMB8 1331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.